NEW YORK (GenomeWeb News) – British molecular diagnostics firm DxS today said that it has doubled its research and development staff from four to eight during the final quarter of this year.
The Manchester-based firm said that it also plans to recruit five more product development scientists within the next month. It said that the increase in staff was due to a “marked rise in demand” for its cancer diagnostic kits.
DxS recently launched a PI3K Mutation Test Kit based on its real-time PCR technology, called Scorpions, and its ARMS SNP detection technology. It sells other kits for detection of cancer-related mutations under the TheraScreen brand name.